719 related articles for article (PubMed ID: 19835880)
1. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
[TBL] [Abstract][Full Text] [Related]
2. Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular Cardiomyocytes.
Savio-Galimberti E; Knollmann BC
PLoS One; 2015; 10(6):e0131179. PubMed ID: 26121139
[TBL] [Abstract][Full Text] [Related]
3. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT.
Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC
Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
[TBL] [Abstract][Full Text] [Related]
6. Ryanodine receptor sensitivity governs the stability and synchrony of local calcium release during cardiac excitation-contraction coupling.
Wescott AP; Jafri MS; Lederer WJ; Williams GS
J Mol Cell Cardiol; 2016 Mar; 92():82-92. PubMed ID: 26827896
[TBL] [Abstract][Full Text] [Related]
7. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation.
Sedej S; Heinzel FR; Walther S; Dybkova N; Wakula P; Groborz J; Gronau P; Maier LS; Vos MA; Lai FA; Napolitano C; Priori SG; Kockskämper J; Pieske B
Cardiovasc Res; 2010 Jul; 87(1):50-9. PubMed ID: 20080988
[TBL] [Abstract][Full Text] [Related]
8. Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.
Bannister ML; Alvarez-Laviada A; Thomas NL; Mason SA; Coleman S; du Plessis CL; Moran AT; Neill-Hall D; Osman H; Bagley MC; MacLeod KT; George CH; Williams AJ
Br J Pharmacol; 2016 Aug; 173(15):2446-59. PubMed ID: 27237957
[TBL] [Abstract][Full Text] [Related]
9. How does flecainide impact RyR2 channel function?
Salvage SC; Huang CL; Fraser JA; Dulhunty AF
J Gen Physiol; 2022 Sep; 154(9):. PubMed ID: 35713932
[TBL] [Abstract][Full Text] [Related]
10. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
[TBL] [Abstract][Full Text] [Related]
11. Prevention of ventricular arrhythmia and calcium dysregulation in a catecholaminergic polymorphic ventricular tachycardia mouse model carrying calsequestrin-2 mutation.
Alcalai R; Wakimoto H; Arad M; Planer D; Konno T; Wang L; Seidman JG; Seidman CE; Berul CI
J Cardiovasc Electrophysiol; 2011 Mar; 22(3):316-24. PubMed ID: 20807279
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Galimberti ES; Knollmann BC
J Mol Cell Cardiol; 2011 Nov; 51(5):760-8. PubMed ID: 21798265
[TBL] [Abstract][Full Text] [Related]
13. Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.
Hwang HS; Nitu FR; Yang Y; Walweel K; Pereira L; Johnson CN; Faggioni M; Chazin WJ; Laver D; George AL; Cornea RL; Bers DM; Knollmann BC
Circ Res; 2014 Mar; 114(7):1114-24. PubMed ID: 24563457
[TBL] [Abstract][Full Text] [Related]
14. Calmodulin kinase II inhibition prevents arrhythmias in RyR2(R4496C+/-) mice with catecholaminergic polymorphic ventricular tachycardia.
Liu N; Ruan Y; Denegri M; Bachetti T; Li Y; Colombi B; Napolitano C; Coetzee WA; Priori SG
J Mol Cell Cardiol; 2011 Jan; 50(1):214-22. PubMed ID: 20937285
[TBL] [Abstract][Full Text] [Related]
15. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
[TBL] [Abstract][Full Text] [Related]
16. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2.
Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ
Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564
[TBL] [Abstract][Full Text] [Related]
17. Flecainide Paradoxically Activates Cardiac Ryanodine Receptor Channels under Low Activity Conditions: A Potential Pro-Arrhythmic Action.
Salvage SC; Gallant EM; Fraser JA; Huang CL; Dulhunty AF
Cells; 2021 Aug; 10(8):. PubMed ID: 34440870
[TBL] [Abstract][Full Text] [Related]
18. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor.
Bannister ML; MacLeod KT; George CH
Br J Pharmacol; 2022 Jun; 179(11):2558-2563. PubMed ID: 34698387
[TBL] [Abstract][Full Text] [Related]
19. Uptake-leak balance of SR Ca
Lopez R; Janicek R; Fernandez-Tenorio M; Courtehoux M; Matas L; Gerbaud P; Gomez AM; Egger M; Niggli E
J Mol Cell Cardiol; 2022 Sep; 170():1-14. PubMed ID: 35644481
[TBL] [Abstract][Full Text] [Related]
20. Flecainide induces a sustained countercurrent dependent effect on RyR2 in permeabilized WT ventricular myocytes but not in intact cells.
Steer EJ; Yang Z; Al-Owais MM; Kirton HM; White E; Steele DS
Front Pharmacol; 2023; 14():1155601. PubMed ID: 37124209
[No Abstract] [Full Text] [Related]
[Next] [New Search]
